IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Sells $4,618,824.58 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded down $1.17 during midday trading on Tuesday, hitting $463.74. The company’s stock had a trading volume of 493,929 shares, compared to its average volume of 726,423. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock’s 50-day moving average price is $429.03 and its 200-day moving average price is $453.28. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a market capitalization of $37.98 billion, a PE ratio of 43.46, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37.

Analyst Ratings Changes

A number of analysts have recently weighed in on IDXX shares. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC increased its stake in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Flossbach Von Storch SE increased its stake in IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares in the last quarter. William Blair Investment Management LLC increased its stake in IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after purchasing an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Finally, Seilern Investment Management Ltd purchased a new position in IDEXX Laboratories in the 4th quarter worth about $113,104,000. 87.84% of the stock is currently owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.